Skip to main content

Table 2 Effect of ARV therapy on plasma viral load levels after 6, 12 and 24 months.

From: Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

  

Baseline VL

VL 6 m

VL 12 m

VL 24 m

Baseline CD4

Delta CD4 12 m

PI-containing regimens

1

AZT-3TC-LPV/r

3.65

U

U

U

40

+ 323

2

d4T-3TC-IDV/r

2.36

U

U

U

490

+ 231

3

d4T-ABC-LPV/r

5.36

D

D

D

338

+180

4

3TC-TDF-SQV-ATV/r

5.73

U

U

NA

92

+161

5

d4T-3TC-NFV

3.36

U

U

U

261

+147

6

TDF-FTC-ATV/r

5.40

D

NA

NA

10

+140

7

AZT-3TC-LPV/r

4.05

U

U

U

62

+136

8

d4T-3TC-IDV

NA

NA

NA

NA

527

+ 89

9

d4T-3TC-LPV/r

4.36

U

U

U

128

+ 67

10

ddI-TDF-IDV/r

3.60

D

U

NA

120

+ 50

11

d4T-3TC-NFV

4.36

D

D

D

380

+ 49

12

AZT-3TC-FPV/r

3.49

D

D

NA

290

+ 40

13

AZT-3TC-IDV

5.29

U

U

D

280

+ 21

14

d4T-3TC-NFV

4.36

D

D

NA

257

- 14

15

3TC-TDF-IDV/r

2.40

D

D

NA

180

- 31

 

Mean

4.13

   

230

+106

 

Median

4.21

   

257

+89

PI-sparing regimens

16

AZT-3TC-ABC

3.01

D

D

D

150

+ 57

17

d4T-3TC-ABC-TDF

3.36

U

U

U

630

+12

18

ddI-TDF-ABC

4.05

D

D

D

174

- 8

19

AZT-3TC-ABC

5.07

D

D

NA

166

- 53

20

AZT-3TC-ABC

2.40

D

NA

NA

737

- 60

21

3TC-ABC-TDF

3.36

NA

D

NA

195

- 61

22

AZT-3TC-ABC

4,78

D

D

D

280

- 62

 

Mean

3.72

   

333

-25

 

Median

3.36

   

195

.53

Regimens not included in the comparison above

23

AZT-3TC-NVP

NNRTI is not active, suboptimal bitherapy

     

24

AZT

Suboptimal monotherapy

     

25

ddI-d4T-EFV

NNRTI is not active, suboptimal bitherapy

     

26

AZT-3TC-NFV

Therapy switched after 1 month

     

27

3TC-ABC-FPV/r

Therapy switched after 1 month

     

28

AZT-3TC-SQV/r

Therapy started end of 2006

     

29

AZT-3TC-LPV/r

Therapy started end of 2006

     

30

AZT

Pregnancy, prevention MTCT

     

31

AZT

Pregnancy, prevention MTCT

     

32

AZT-3TC-LPV/r

Pregnancy, prevention MTCT

     

33

3TC-d4T

Lost to follow-up

     

34

ddI-d4T-ABC-SQV-NFV

Lost to follow-up

     
  1. Regimens were classified within the PI-containing and PI-sparing groups from the highest to the lowest delta CD4 counts after 12 months of therapy.
  2. Baseline viral load levels are expressed in log copies/ml of plasma, CD4 counts are expressed in cells/mm3.
  3. All regimens are first line therapies, except regimens 3, 4, 7 and 18 to 22 which are second line therapies; 6, 10, 17, 21 are third line therapies and 15 is a fourth line therapy.
  4. U = undetectable plasma viral load; D = detectable viral load; NA = not available (unavailable sample or end of the treatment); MTCT = mother to child transmission.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us